Grifols saves Spanish Alzheimer's vaccine developer Araclon
This article was originally published in Scrip
Executive Summary
Spanish plasma derivatives producer Grifols has stepped in to save Araclon Biotech, a spin-off of the Spanish University of Zaragoza in Aragon which is developing an immunotherapy for Alzheimer's disease as well as early diagnosis kits for the disease. Grifols has taken a 51% shareholding in the company through its investment vehicle, Gri-Cel, which it set up in 2010 to enable it to get involved in new fields of medicine which lie outside the main focus of its activities.